Plasma biomarkers, which are both accessible and inexpensive, have recently become available and have been found to be associated with brain Aβ burden, tau pathology, and neurodegeneration, as well as the likelihood of clinical progression to dementia. This evidence concerns the gene MAPT and dementia.